Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review

Area of Science:

• Pulmonary Medicine
• Pharmacology

Background:

• Fixed-dose combinations (FDCs) of long-acting bronchodilators, specifically long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are established treatments for chronic obstructive pulmonary disease (COPD).
• Previous studies indicate these FDCs enhance lung function (e.g., forced expiratory volume in 1 second [FEV1]) more than monotherapy, but patient-reported outcomes (PROs) show less consistent improvement.

Purpose of the Study:

• To systematically evaluate the impact of LAMA-LABA FDCs on PROs in COPD patients.
• To assess the relationship between improvements in lung function and PROs following treatment with LAMA-LABA FDCs.

Main Methods:

• A systematic literature search identified Phase III randomized controlled trials (RCTs) of LAMA-LABA FDCs for COPD treatment.
• Two independent reviewers assessed study results, with a third reviewer resolving discrepancies.
• Included trials focused on specific FDCs: indacaterol/glycopyrronium, umeclidinium/vilanterol, tiotropium/olodaterol, and aclidinium/formoterol.

Main Results:

• LAMA-LABA FDCs significantly improved lung function compared to monotherapies or other single-agent treatments.
• These FDCs generally led to improvements in patient-reported symptoms and health status compared to monotherapies.
• Observed discrepancies between lung function improvements and PROs were noted in some studies.
• The safety profiles of the FDCs were comparable to placebo.

Conclusions:

• LAMA-LABA FDCs are effective in improving lung function and generally benefit PROs in COPD patients.
• While lung function improvements often correlate with better symptoms, some inconsistencies warrant further investigation.
• Additional research is necessary to fully elucidate the relationship between lung function changes and PROs in patients using these combination therapies.